Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Eidos Therapeutics logo — Pioneering genetically targeted therapies to swiftly transla...

Eidos Therapeutics

Pioneering genetically targeted therapies to swiftly translate breakthrough science into life-changing treatments.

Founded 2013 Series B Total: $64.00M Biopharma, Biotechnology +1

General Information

Company Name Eidos Therapeutics
Founded Year 2013
Founders / Decision Makers
Team member
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Eidos Therapeutics. To contact Eidos Therapeutics, visit eidostx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Eidos Therapeutics compare?

A PDF of Eidos Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Eidos Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Eidos Therapeutics

Eidos Therapeutics is a pioneering biotech company with a mission to swiftly translate breakthrough science into life-changing treatments. Founded in 2013, the company operates in the Biopharma, Biotechnology, and Pharmaceutical industries. Through a distinctive corporate structure, Eidos Therapeutics merges traditional drug development with innovative, genetically targeted therapies aimed at addressing diseases at their core.

The latest milestone for Eidos Therapeutics was a significant $64.00M Series B investment on 05 April 2018, led by a consortium of prominent investors including RA Capital Management, Aisling Capital, Cormorant Asset Management, Perceptive Advisors, Viking Global Investors, Amzak Health Investors, BridgeBio, and Janus Henderson.

By attracting such substantial investments from key players in the financial market, Eidos Therapeutics exhibits strong potential in the biotech sector, making it a compelling prospect for venture capital firms seeking promising opportunities in the field of genetically targeted therapies.

Business keywords: biotech company, genetically targeted therapies, clinical-stage, drug development, treatment innovation, scientific research, disease targeting, novel therapies, patient-centric approach, corporate structure, early stage science, life-changing treatments

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $64.00M 8
RA Capital Management Aisling Capital Perceptive Advisors
RA Capital Management, Aisling Capital +6
05 Apr 2018

Eidos Therapeutics Alternatives & Competitors

View All Alternatives
Eidos Therapeutics vs
Biomed Valley Discoveries
Biomed Valley Discoveries United States

Biotech, Purposefully Reimagined

11 employees
Biotechnology, Health Care
Eidos Therapeutics vs
Antengene
Antengene China

Treating Patients Beyond Borders.

Series C
69 employees
Biopharma, Biotechnology
Eidos Therapeutics vs
Yuanyin Bio
Yuanyin Bio

Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs...

Series A
Biopharma, Biotechnology
Also compare with: Eidos Therapeutics vs Gilgamesh Pharmaceuticals Gilgamesh Pharmaceuticals View all alternatives

FAQ About Eidos Therapeutics

Pioneering genetically targeted therapies to swiftly translate breakthrough science into life-changing treatments.
Eidos Therapeutics was founded in 2013.
Eidos Therapeutics operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on biotech company, genetically targeted therapies, clinical-stage and drug development.
Eidos Therapeutics has completed 1 funding round, raising a total of $64.00M. The latest funding stage is Series B.
Top alternatives and competitors to Eidos Therapeutics include Biomed Valley Discoveries, Antengene, Yuanyin Bio, PaxMedica, Inc., CaSRevolution. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Eidos Therapeutics and Biomed Valley Discoveries are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Eidos Therapeutics, https://bouncewatch.com/company/eidos-therapeutics, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout